Helius Medical Technologies, Inc. (HSDT)
| Market Cap | 3.67M |
| Revenue (ttm) | 668,000 |
| Net Income (ttm) | -8.87M |
| Shares Out | 2.96M |
| EPS (ttm) | -12.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 113,159 |
| Open | 1.160 |
| Previous Close | 1.180 |
| Day's Range | 1.120 - 1.250 |
| 52-Week Range | 1.110 - 13.430 |
| Beta | 1.59 |
| Analysts | Strong Buy |
| Price Target | 24.00 (+1,835.48%) |
| Earnings Date | May 13, 2024 |
About HSDT
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. Heliu... [Read more]
Financial Performance
In 2023, HSDT's revenue was $644,000, a decrease of -18.17% compared to the previous year's $787,000. Losses were -$8.85 million, -37.11% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for HSDT stock is "Strong Buy" and the 12-month stock price forecast is $24.0.
News
Helius Medical Technologies, Inc. to Present at the Spring MicroCap Rodeo Conference
NEWTOWN, PA / ACCESSWIRE / May 31, 2024 / Helius Medical Technologies, Inc., (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation ap...
Helius Medical Technologies to Exhibit at 2024 CMSC Annual Meeting, Marking a Year of Achievements: Making PoNS More Available to People with MS
Company Will Highlight Major Milestones on Accessibility and Reimbursement Fronts Company Will Highlight Major Milestones on Accessibility and Reimbursement Fronts
Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts
-- Approval provides U.S. veterans and other U.S. government agency employees who suffer gait and balance impairment due to multiple sclerosis (MS) access to the only portable neurostimulation therapy...
Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results
NEWTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulatio...
Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024
NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...
Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering
NEWTOWN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
-- Helius Medical and Shepherd Center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke -- -- Shepherd Center, a top neurorehabilitation hospital, is the...
Helius Medical stock rallies 40%: explore why
Helius Medical Technologies Inc (NASDAQ: HSDT) is up close to 40% in premarket on Wednesday after teaming up with Lovell Government Services. Why is it good news for Helius Medical stock?
Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) -- -- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually -- ...
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on ...
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodula...
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke
-- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month -- -- Study will evaluate the use of Portable Neuromodulation Stimulator (PoNS®) for gait and balance deficits in ...
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulat...
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
-- Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) -- -- Proceeds from recent stock issuances thro...
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
-- Studies uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in stroke patients -- -- Interaction with FDA on clinical p...
Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists' Ability to Customize PoNS Therapy® to Improve Gait in People with MS
Event Appearance Caps Year of Growth: PoNS®-Trained PTs Now Found Across the United States Event Appearance Caps Year of Growth: PoNS®-Trained PTs Now Found Across the United States
Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital
-- Brooks Rehabilitation Hospital adds a second site to the registrational program in stroke, and brings the total number of patients to 100 -- -- Study uses Portable Neuromodulation Stimulator (PoNS®...
Helius Medical Technologies to Present at NobleCon19 Annual Conference
NEWTOWN, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...
Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy™ Helps Patients with Traumatic Brain Injury Return to Work
-- Collaborative project between Pacific Blue Cross and HealthTech Connex designed to reduce long-term disability and improve quality of life for individuals suffering from traumatic brain injury (“TB...
Helius Medical Technologies, Inc. to Release Third Quarter 2023 Financial Results on November 9, 2023; Announces Extended Cash Runway into Q2 2024
-- Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023 -- -...
Helius Medical Technologies, Inc. Receives Letter of Intent from the Québec Ministry of Health and Social Services to Purchase 30 PoNS® Devices
-- PoNS® devices to be provided to a least five sites in five separate administrative regions within Québec ---- Government-funded initiative will evaluate the benefits of PoNS Therapy™ when used by p...
Helius Medical Technologies to Participate at Two Upcoming Healthcare Conferences
NEWTOWN, Pa., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...
Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece
-- UPC numbers assigned by Wolters Kluwer Health, provider of trusted clinical technology ---- PoNS system and mouthpiece will be included in pharmacy database utilized by 17 out 20 of the top-grossin...
Helius to Bring its Innovative PoNS Therapy for Improvement of Gait in People with MS, to the 2023 Academy of Neurologic Physical Therapy Conference
Company's First-Ever ANPT Booth Sponsorship Enables Specialists to Learn More about this Breakthrough Technology on Eve of National Physical Therapy Month
University of Montreal's School of Rehabilitation to Purchase Ten PoNS® Devices for Research Study on Stroke Recovery
-- The study will evaluate the optimal time to use PoNS Therapy™ during a patient's stroke recovery journey -- -- The study will evaluate the optimal time to use PoNS Therapy™ during a patient's strok...